ArmstrongEJAlamSHenaoS, et al. Multidisciplinary care for critical limb ischemia: current gaps and opportunities for improvement. J Endovasc Ther. 2019;26:199–212.
2.
KawaradaOSakamotoSHaradaK, et al. Contemporary crossing techniques for infrapopliteal chronic total occlusions. J Endovasc Ther. 2014;21:266–280.
3.
GiannopoulosSArmstrongEJ.Newly approved devices for endovascular therapy of femoropopliteal disease: a review of clinical evidence. Exp Rev Cardiovasc Ther. 2019;17:729–740.
4.
KimTISchneiderPA.New innovations and devices in the management of chronic limb-threatening ischemia. J Endovasc Ther. 2020;27(4):524–539.
5.
MustaphaJASaabFAMartinsenBJ, et al. Digital subtraction angiography prior to an amputation for critical limb ischemia (CLI): an expert recommendation statement from the CLI Global Society to Optimize Limb Salvage. J Endovasc Ther. 2020;27(4):540–546.
6.
GiannopoulosSVarcoeRLLichtenbergM, et al. Balloon angioplasty of infrapopliteal arteries: a systematic review and proposed algorithm for optimal endovascular therapy. J Endovasc Ther. 2020;27(4):547–564.
7.
FujiharaMYazuYTakaharaM.Intravascular ultrasound–guided interventions for below-the-knee disease in patients with chronic limb-threatening ischemia. J Endovasc Ther. 2020;27(4):565–574.
8.
ShammasNWShammasWJJones-MillerS, et al. Optimal vessel sizing and understanding dissections in infrapopliteal interventions: data from the iDissection below the knee study. J Endovasc Ther. 2020;27(4):575–580.
9.
MenardMTFarberAAssmannSF, et al. Design and rationale of the best endovascular versus best surgical therapy for patients with critical limb ischemia (BEST-CLI) trial. J Am Heart Assoc. 2016;5:e003219.
10.
UtsunomiyaMTakaharaMIidaO, et al. Limb-based patency after surgical vs endovascular revascularization in patients with chronic limb-threatening ischemia. J Endovasc Ther. 2020;27(4):584–594.
11.
ConteMSBradburyAWKolhP, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69:3S–125S.
12.
StavroulakisKGkremoutisABorowskiM, et al; CRITISCH Collaborators. Bypass grafting vs endovascular therapy in patients with non-dialysis-dependent chronic kidney disease and chronic limb-threatening ischemia (CRITISCH Registry). J Endovasc Ther. 2020;27(4):599–607.
13.
OkamotoSIidaOTakaharaM, et al. A global vascular guidelines-based bypass-preferred population and their surgical risk among CLTI patients treated with endovascular therapy in a real-world practice. J Endovasc Ther. 2020;27(4):608–613.
14.
KumSIpemaJChun-YinDH, et al. Early and midterm experience with the Absorb everolimus-eluting bioresorbable vascular scaffold in Asian patients with chronic limb-threatening ischemia: one-year clinical and imaging outcomes from the DISAPEAR Registry. J Endovasc Ther. 2020;27(4):616–622.
GeraghtyPJAdamsGLSchmidtA, et al; TOBA II BTK Investigators. Twelve-month results of Tack-optimized balloon angioplasty in below-the-knee arteries (TOBA II BTK). J Endovasc Ther. 2020;27(4):626–636.
17.
KokkinidisDGKatamreddyAGiannopoulosS, et al. Risk models and scores in patients with peripheral artery disease and chronic limb threatening ischemia: a comprehensive review [published online May 30, 2020]. Curr Pharm Des. doi:10.2174/1381612826666200530214459
18.
HataYIidaOTakaharaM, et al. Infrapopliteal anatomic severity and delayed wound healing in patients with chronic limb-threatening ischemia in the era of the global limb anatomic staging system. J Endovasc Ther. 2020;27(4):641–646.
19.
KatsanosKSpiliopoulosSKitrosP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
20.
SecemskyEAKundiHWeinbergI, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4:332–340.
21.
GiannopoulosSJeon-SlaughterHKahlonRS, et al. Comparative 12-month outcomes of drug-coated balloon versus non-drug-coated balloon revascularization strategy in chronic limb threatening ischemia: results from the XLPAD registry [published online March 27, 2020]. Cardiovasc Revasc Med. doi:10.1016/j.carrev.2020.03.030
22.
ReijnenMMPJvan WijckIZellerT, et al. Outcomes after drug-coated balloon treatment of femoropopliteal lesions in patients with critical limb ischemia: a post hoc analysis from the IN.PACT Global Study. J Endovasc Ther. 2019;26:305–315.
23.
GiannopoulosSGhanianSParikhSA, et al. Safety and efficacy of drug-coated balloon angioplasty for the treatment of chronic limb-threatening ischemia: a systematic review and meta-analysis. J Endovasc Ther. 2020;27(4):647–657.
24.
KumSTanYKSchreveMA, et al. Midterm outcomes from a pilot study of deep vein arterialization for the treatment of no-option critical limb ischemia. J Endovasc Ther. 2017;24:619–626.
25.
SchmidtASchreveMAHuizingE, et al. Midterm outcomes of percutaneous deep venous arterialization with a dedicated system for patients with no-option chronic limb-threatening ischemia: the ALPS multicenter study. J Endovasc Ther. 2020;27(4):658–665.
26.
HammadTARundbackJBunteM, et al. Stromal cell-derived factor-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD) Trial: six-month results. J Endovasc Ther. 2020;27(4):669–675.
